'Legacy Effects' of Statins: 14% Reduction in Mortality

[carlita]

August 28, 2011 (Paris, France) — Long-term results of the Anglo-Scandinavian Cardiac Outcomes--Lipid-Lowering Arm (ASCOT-LLA) study, eight years after the trial officially stopped, showed that treatment with 10 mg of atorvastatin (Lipitor, Pfizer) reduced all-cause mortality compared with placebo, mainly through a reduction in noncardiovascular deaths [1].
......


Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος

[WebGP]

"The results of ASCOT-LLA were first presented and simultaneously published online in the Lancet in 2003 [2]. As reported by heartwire , lipid lowering with atorvastatin resulted in a significant 36% reduction in the primary end point of fatal coronary heart disease and nonfatal MI after a median follow-up of 3.3 years. At the time the study was stopped, there was a nonsignificant trend toward reduction in all-cause mortality. Upon completion of ASCOT-LLA, investigators continued to collect mortality data and evaluated the mortality outcomes in participants originally randomized to atorvastatin or placebo in the ASCOT-LLA arm for a median of 11 years.

At the end of the extended follow-up, all-cause mortality was significantly reduced by 14% (hazard ratio 0.86; 95% CI 0.76–0.98), and noncardiovascular mortality was significantly reduced by 15% (HR 0.85; 95% CI 0.73–0.99). There was no difference in death from cardiovascular causes."

Δηλαδή, όπως το καταλαβαίνω εγώ τουλάχιστον, μέχρι τα 3,3 πρώτα χρόνια χρήσης ατορβαστατίνης έχουμε μια μείωση των θανάτων κατά 36%, δηλαδή κατά 1/3 περίπου. Μετά τα 11 χρόνια όμως η γενική θνησιμότητα (απ' όλες τις αιτίες μειώθηκε κατά 14%) ενώ στους θανάτους από καρδιαγγειακά αίτια δεν υπήρχε καμία διαφορά.